![Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study]()
Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm studyRosenfeld, Margaret; Wainwright, Claire E; Higgins, Mark; Wang, Linda T; McKee, Charlotte; Campbell, Daniel; Tian, Simon; Schneider, Jennifer; Cunningham, Steve; Davies, Jane C; Rosenfeld, Margaret; Wainwright, Claire E.; Higgins, Mark; Wang, Linda T.; McKee, Charlotte; Campbell, Daniel; Tian, Simon; Schneider, Jennifer; Cunningham, Steve; Davies, Jane C.; Harris, William; Mogayzel, Peter; McCoy, Karen; Milla, Carlos; Rubenstein, Ronald; Walker, Seth; Black, Philip; Montgomery, Gregory; McColley, Susanna; Hiatt, Peter; Sawicki, Gregory; Rock, Michael; Aurora, Paul; Ratjen, Felix; Maitra, Anirban; Ives, Andrew; Gaillard, Erol; McNalley, Paul; Selvadurai, Hiranjan; Robinson, Philip · The Lancet Respiratory Medicine · 2018